Evaluation of tamoxifen and metabolites by LC-MS/MS and HPLC methods

British Journal of Biomedical Science

Volumn 71, Issue 1, 2014, Pages 33-39

  Heath, Dennis D ^a   Flatt, S W ^a   Wu, A H B ^b   Pruitt, M A ^a   Rock, C L ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

4 hydroxytamoxifen; Breast neoplasms; Chromatography, high performance liquid; Chromatography, liquid; Endoxifen; Tamoxifen; Tandem mass spectrometry

Indexed keywords

AFIMOXIFENE; ENDOXIFEN; NORTAMOXIFEN; TAMOXIFEN;

ARTICLE; AUTOMATION; BLOOD SAMPLING; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; ISOMER; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MEASUREMENT ACCURACY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

ANTINEOPLASTIC AGENTS, HORMONAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; FLUORESCENCE; HUMANS; MASS SPECTROMETRY; TAMOXIFEN;

EID: 84898010984     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2014.11669960     Document Type: Article

References (22)

1. Lu WJ, Desta Z, Flockhart DA. Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res Treat 2012; 131 (2): 473-81.
2. Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007; 101 (1): 113-21. (Pubitemid 47555336)
3. Johnson MD, Zuo H, Lee KH et al . Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004; 85 (2): 151-9. (Pubitemid 38987269)
4. Jordan VC, Bain RR, Brown RR, Gosden B, Santos MA. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res 1983; 43 (3): 1446-50. (Pubitemid 13160084)
5. Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 791 (1-2): 245-53. (Pubitemid 36638757)
6. Adam HK, Douglas EJ, Kemp JV. The metabolism of tamoxifen in humans. Biochem Pharmacol 1979; 28 (1): 145-7.
7. Fromson JM, Pearson S, Bramah S. The metabolism of tamoxifen (I.C.I. 46,474). II. In female patients. Xenobiotica 1973; 3 (11): 711-4.
8. Mendenhall DW, Kobayashi H, Shih FM, Sternson LA, Higuchi T, Fabian C. Clinical analysis of tamoxifen, an anti-neoplastic agent, in plasma. Clin Chem 1978; 24 (9): 1518-24. (Pubitemid 9018440)
9. Golander Y, Sternson LA. Paired-ion chromatographic analysis of tamoxifen and two major metabolites in plasma. J Chromatogr 1980; 181 (1): 41-9. (Pubitemid 10145640)
10. Gaskell SJ, Daniel CP, Nicholson RI. Determination of tamoxifen in rat plasma by gas chromatography-mass spectrometry. J Endocrinol 1978; 78 (2): 293-4. (Pubitemid 8404822)
11. Daniel CP, Gaskell SJ, Bishop H, Nicholson RI. Determination of tamoxifen and an hydroxylated metabolite in plasma from patients with advanced breast cancer using gas chromatography-mass spectrometry. J Endocrinol 1979; 83 (3): 401-8. (Pubitemid 10207532)
12. Murphy C, Fotsis T, Pantzar P, Adlercreutz H, Martin F. Analysis of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen levels in cytosol and KCl-nuclear extracts of breast tumours from tamoxifen treated patients by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). J Steroid Biochem 1987; 28 (6): 609-18. (Pubitemid 18024980)
13. Brown RR, Bain R, Jordan VC. Determination of tamoxifen and metabolites in human serum by high-performance liquid chromatography with post-column fluorescence activation. J Chromatogr 1983; 272 (2): 351-8. (Pubitemid 13149624)
14. Lien EA, Ueland PM, Solheim E, Kvinnsland S. Determination of tamoxifen and four metabolites in serum by low-dispersion liquid chromatography. Clin Chem 1987; 33 (9): 1608-14. (Pubitemid 18089614)
15. Stevenson D, Briggs RJ, Chapman DJ, De Vos D. Determination of tamoxifen and five metabolites in plasma. J Pharm Biomed Anal 1988; 6 (6-8): 1065-8.
16. Fried KM, Wainer IW. Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography. J Chromatogr B Biomed Appl 1994; 655 (2): 261-8. (Pubitemid 24169259)
17. Lu W, Poon GK, Carmichael PL, Cole RB. Analysis of tamoxifen and its metabolites by on-line capillary electrophoresis-electrospray ionization mass spectrometry employing nonaqueous media containing surfactants. Anal Chem 1996; 68 (4): 668-74.
18. Sanders JM, Burka LT, Shelby MD, Newbold RR, Cunningham ML. Determination of tamoxifen and metabolites in serum by capillary electrophoresis using a nonaqueous buffer system. J Chromatogr B Biomed Sci Appl 1997; 695 (1): 181-5. (Pubitemid 27308619)
19. Lim HK, Stellingweif S, Sisenwine S, Chan KW. Rapid drug metabolite profiling using fast liquid chromatography, automated multiple-stage mass spectrometry and receptor-binding. J Chromatogr A 1999; 831 (2): 227-41. (Pubitemid 29073708)
20. Zhu YB, Zhang Q, Zou JJ, Yu CX, Xiao DW. Optimizing high-performance liquid chromatography method with fluorescence detection for quantification of tamoxifen and two metabolites in human plasma: application to a clinical study. J Pharm Biomed Anal 2008; 46 (2): 349-55.
21. Madlensky L, Natarajan L, Tchu S et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2011; 89 (5): 718-25.
22. Tchu SM, Lynch KL, Wu AH. Therapeutic drug monitoring of tamoxifen using LC-MS/MS. Methods Mol Biol 2012; 902: 211-22.